Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients

• DOI: 10.1186/s40364-022-00400-5
• Publication Date: 2022-07-29T11:03:59Z
• Authors: Jun Lu; Jun Wu; Yuqing Lou; Qin Shi; Jun Xu; Lele Zhang; Wei Nie; Jie Qian; Yanan Wang; Yanwei Zhang; Jing Jiao; Xueyan Zhang; Wei Zhang; Huimin Wang; Tianqing Chu; Hua Zhong; Baohui Han
• Keywords: Atezolizumab

Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess ctDNA sequencing-based mutation index (TMI) screening responders (from non-responders) among NSCLC patients who received monotherapy with docetaxel or atezolizumab.We performed retrospective analysis POPLAR (NCT01903993) and OAK (NCT02008227) trials. We identified three biomarkers, blood burden (bTMB), sensitive (sbTMB) unfavourable score (UMS), profiles. After integrating advantages disadvantages independent developed TMI may benefit from atezolizumab in terms overall survival (OS).The as biomarker provided median OS duration 5.55 months longer than non-responders cohort, significantly decreased hazard ratio (HR). Moreover, had 10.21-month advantage over cohort via stratification, HR was also significantly. The demonstrated effectiveness stratifying cohort. Importantly, found that could screen additional upon combining cohorts trials after adjustment.In present study, novel 2nd-line atezolizumab. believe will potentially be effective clinical treatment future.